Biotech Values

[dewophile]

3-5 years is a long time for an oral agent to attempt to expand its indications and maybe gain traction.

This may never happen, but given the uncertainty, it may be difficult to get a partner to put up hundreds of million to bring this to a market that may look radically different in 5 years.

i think this is hurting negotiations, but as dew has pointed out the oral Xa inhibitors are not looking all that promising in ACS. the oral thrombin inhibitor may fare better, but if M118 can best angiomax (another direct thrombin inhibitor) then i think it stands to reason docs will perceive Xa with IIa inhibition the best route in ACS and M118 will find a commercial home

And all this, ironically, in competition with a much cheaper generic lovenox as well

lovenox is not that cheap even with menox on the market, and doesn't inhibit thrombin so is not used much in the M118 space. more cconcerning is that angiomax will also be nearing its patent expiry by the time m118 theoretically hits the scene.

if no partners are biting now then mnta likely needs to run a fairly robust 2b against angiomax. it will be costly, but if successful the upside could be substantial

jmo